Among the nuclear medicine molecular targets, conventional bone-seeking agents (high myocardial uptake is associated with ATTR CA subtypes, hereditary and wild-type), and amyloid PET {high myocardial uptake of 11C-PIB, 18F-Flutemetamol or 18F-Florbetaben has been associated with the AL CA subtype [13] and ATTRV30M amyloidosis [14]} have emerged as key procedures for the non-invasive etiologic diagnosis of cardiac amyloidosis (CA), allowing for the early instigation of therapy. Here, TTR is linked to amyloidosis.